prikaz prve stranice dokumenta CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
  Preuzmi
PDF 271.56 KB
Znanstveni rad - Izvorni znanstveni rad
CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
International Journal of Molecular Sciences, 25 (2024), 13; 7412. https://doi.org/10.3390/ijms25137412
Nekić, Jasna; Stanković Matić, Ivana; Rački, Valentino; Janko Labinac, Dolores; Vuletić, Vladimira; Kapović, Miljenko; Ristić, Smiljana; Peterlin, Borut; Starčević Čizmarević, Nada

Citirajte ovaj rad

Nekić, J., Stanković Matić, I., Rački, V., Janko Labinac, D., Vuletić, V., Kapović, M. ... Starčević Čizmarević, N. (2024). CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients. International Journal of Molecular Sciences, 25. (13). doi: 10.3390/ijms25137412

Nekić, Jasna, et al. "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients." International Journal of Molecular Sciences, vol. 25, br. 13, 2024. https://doi.org/10.3390/ijms25137412

Nekić, Jasna, Ivana Stanković Matić, Valentino Rački, Dolores Janko Labinac, Vladimira Vuletić, Miljenko Kapović, Smiljana Ristić, Borut Peterlin i Nada Starčević Čizmarević. "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients." International Journal of Molecular Sciences 25, br. 13 (2024). https://doi.org/10.3390/ijms25137412

Nekić, J., et al. (2024) 'CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients', International Journal of Molecular Sciences, 25(13). doi: 10.3390/ijms25137412

Nekić J, Stanković Matić I, Rački V, Janko Labinac D, Vuletić V, Kapović M, i sur.. CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients. International Journal of Molecular Sciences [Internet]. 05.07.2024. [pristupljeno 11.11.2024.];25(13). doi: 10.3390/ijms25137412

J. Nekić, et al., "CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients", International Journal of Molecular Sciences, vol. 25, br. 13, Srpanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:033424. [Citirano: 11.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:033424
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients
AutorJasna Nekić
AutorIvana Stanković Matić
AutorValentino Rački
AutorDolores Janko Labinac
AutorVladimira Vuletić
AutorMiljenko Kapović
AutorSmiljana Ristić
AutorBorut Peterlin
AutorNada Starčević Čizmarević
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za neurologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Sažetak (engleski)
The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and non-responders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 25, br. 13, 7412
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms25137412
URN:NBNurn:nbn:hr:184:033424
Datum objave publikacije2024-07-05
ProjektŠifra: uniri-biomed-18-137
Naziv (hrvatski): Farmakogenetika multiple skleroze: odgovor na imunomodulacijsku terapiju
Naziv (engleski): Farmacogenetics of multiple sclerosis: response to disease-modifying therapy
Voditelj: Nada Starčević Čizmarević
Pravna nadležnost: Hrvatska
Financijer: Medicinski fakultet u Rijeci
URL dokumentahttps://www.mdpi.com/1422-0067/25/13/7412
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-11-11 09:51:54